{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:24:32Z","timestamp":1787714672355,"version":"build-2784847793"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to determine whether the short\u2010term response to biologics in biologic\u2010naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis. Patients were considered in the early treatment group if they had started on biologic therapy within two years of PsA diagnosis; otherwise, they were considered in the delayed treatment group. The primary outcome was \u226550% reduction in the Disease Activity Index for Psoriatic Arthritis (DAPSA) score at six months. The secondary outcome was Psoriasis Area and Severity Index (PASI) 75, defined as \u226575% improvement in the PASI score at six months. Logistic regression was used to examine the association between early treatment and disease outcomes at six months. Propensity scores were used to account for differences between the groups at the baseline visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 228 included patients, 71 patients were in the early treatment group, and 157 patients were in the delayed treatment group. There were significant differences in the time from PsA diagnosis to biologic treatments over the decades. The propensity score regression adjusted analysis did not suggest a difference in response at six months between those treated within two years of diagnosis and those treated later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Short\u2010term response to biologic therapy in patients with PsA does not appear to differ between those treated early or later in the disease course. It remains to be determined whether early treatment prevents progression of joint damage in the longer\u2010term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.80120","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:46:37Z","timestamp":1784699197000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short\u2010Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy"],"prefix":"10.1002","author":[{"given":"Sung Min","family":"Cho","sequence":"first","affiliation":[{"name":"Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Gao","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, Toronto Western Hospital University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, Toronto Western Hospital University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Statistics and Actuarial Science University of Waterloo  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, Toronto Western Hospital University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_6_4_1","first-page":"1072","article-title":"Trends in mortality and cause\u2010specific mortality among patients with psoriatic disease in Ontario","volume":"47","author":"Colaco K","year":"2020","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081860"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0618-5"},{"key":"e_1_2_6_8_1","unstructured":"Ontario Rheumatology Association.Exceptional Access Program (EAP): psoriatic arthritis (PsA). Accessed July 1 2025.https:\/\/ontariorheum.ca\/exceptional-access-program\/psoriatic-arthritis-psa"},{"key":"e_1_2_6_9_1","unstructured":"Ontario Rheumatology Association.Request for biologics for psoriatic arthritis (PsA)\/ seronegative arthritis Exceptional Access Program (EAP). Accessed July 1 2025https:\/\/ontariorheum.ca\/images\/uploads\/content_documents\/PsA_Form-aug11b.pdf"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150938"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00156-0"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00223-1"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.111"},{"issue":"1","key":"e_1_2_6_15_1","first-page":"11","article-title":"Early treatment of psoriatic arthritis is associated with improved patient\u2010reported outcomes: findings from the etanercept PRESTA trial","volume":"33","author":"Kirkham B","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"e_1_2_6_16_1","first-page":"287","article-title":"Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt \u2010 EARLY PsA","volume":"42","author":"Santos H","year":"2017","journal-title":"Acta Reumatol Port"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq262"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.7.760"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"issue":"4","key":"e_1_2_6_21_1","first-page":"238","article-title":"Severe psoriasis\u2010\u2010oral therapy with a new retinoid","volume":"157","author":"Fredriksson T","year":"1978","journal-title":"Dermatologica"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6207"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.80120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:09:44Z","timestamp":1787713784000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.80120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":22,"alternative-id":["10.1002\/acr.80120"],"URL":"https:\/\/doi.org\/10.1002\/acr.80120","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"2026-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acr.80120"}}